Prevention of VZV reactivation using long-term low-dose valacyclovir after allogeneic hematopoietic stem cell transplantation.

Prevention of VZV reactivation using long-term low-dose valacyclovir after allogeneic hematopoietic stem cell transplantation. - Prevention of VZV reactivation using long-term low-dose VCV.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000348

Enrollment

Registered

2006-03-10

Start date

2002-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allogeneic hematopoietic stem cell transplantation recipients

Interventions

Start valacyclovir at 500mg/day thrice weekly from day 36 after transplantation.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: allogeneic hematopoietic stem cell transplantation recipients

Exclusion criteria

Exclusion criteria: Patients with hematological malignancies not in remission. Severe organ dysfunction

Design outcomes

Primary

Measure	Time frame
Incidence of VZV reactivation within 2 years after transplantation.	—

Countries

Japan

Contacts

Public ContactYoshinobu Kanda

University of Tokyo Hospital Department of Hematology & Oncology

ycanda-tky@umin.ac.jp03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026